CMO
Ratio Therapeutics
Colin Hayward is Chief Medical Officer of Ratio Therapeutics. He is a board certified pharmaceutical physician (UK Faculty of Pharmaceutical Medicine) with 25 years' oncology drug development experience. Previously he has worked in drug development at Roche on products like rituximab and bevacizumab also working at Myriad Genetics and Premier Research. Before Ratio Therapeutics, Colin was Chief Medical Officer of Telix Pharmaceuticals working on radiopharmaceutical diagnostics and therapeutics in prostate and renal cancer as well as glioblastoma.